Sandoz

First U.S. biosimilar approval opens floodgates for lower-priced competition to blockbuster biologics

Monday, March 16, 2015 08:00 AM

The FDA’s approval this month of the first U.S biosimilar, Zarxio from Sandoz, has formally opened the floodgates for sponsors seeking approval of lower-cost biologics to compete with expensive brand-name prescription drugs.

More... »


FDA approves first biosimilar Zarxio from Sandoz

Friday, March 6, 2015 12:24 PM

Sandoz, a Novartis company, has became the first company to receive approval of a biosimilar in the U.S. through the new FDA biosimilar pathway established under the Biologics Price Competition and Innovation Act.

More... »


Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Monday, March 2, 2015 08:00 AM

Huntingdon Life Sciences, a British non-clinical CRO that acquired U.S. CRO Harlan Laboratories nine months ago, has launched a rebranding of the combined companies and has set its expansion sights on competing against early-phase giants Charles River Laboratories and Covance.

More... »

3SBio acquires Sirton Pharmaceuticals

Monday, January 26, 2015 02:25 PM

3SBio, a China-based biotechnology company, has acquired the entire share capital of Sirton Pharmaceuticals, located in Villa Guardia, Italy, from First Shanghai, a financial services provider.

More... »

As GSK restructuring cuts 900 jobs in RTP, Parexel absorbs 450 of them in new business unit

Monday, December 8, 2014 01:30 PM

GlaxoSmithKline’s global restructuring was felt sharply in North Carolina this week as it announced plans to cut 900 jobs in Research Triangle Park (RTP), where it has 2,500 employees and contractors working in research and development.

More... »

UCB to sell generics business to private equity firms Advent, Avista Capital for $1.525 billion

Monday, November 10, 2014 12:26 PM

Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, have agreed to acquire UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals (KU). UCB is a multinational biopharmaceutical manufacturing company headquartered in Brussels, Belgium.

More... »

Report: Biosimilars could create $44B in healthcare savings

Wednesday, November 5, 2014 12:52 PM

Introducing competing biosimilar versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the U.S. by $44 billion over the next decade, according to a new analysis from RAND, a Boston, Mass.-based nonprofit research organization that develops solutions to public policy challenges.

More... »

Cinven to invest in Medpace

Monday, February 24, 2014 12:40 PM

European private equity firm Cinven has announced a majority investment in Medpace, for $915 million plus certain cash inflows relating to the period of ownership, acquired from CCMP Capital Advisors.

More... »

PTC Therapeutics appoints Zeldis to board of directors

Thursday, October 4, 2012 12:14 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has appointed Jerome B. Zeldis, M.D., Ph.D., to the company's board of directors.

More... »

DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

More... »


CWWeekly

July 6

FDA sued by advocacy groups seeking hepatitis C trials data

Google to test health-tracking wristband to collect clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs